Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Belinostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acrotech Announces the Publication of Data From a Phase 1 Study of BELEODAQ®
    Acrotech Announces the Publication of Data From a Phase 1 Study of BELEODAQ®

    26 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210426005126/en/Acrotech-Biopharma-Announces-the-Publication-of-Data-From-a-Phase-1-Study-of-BELEODAQ%C2%AE-belinostat-Combined-With-Standard-CHOP-Bel-CHOP-in-Patients-With-Previously-Untreated-Peripheral-T-cell-Lymphoma

    BUSINESSWIRE
    26 Apr 2021
    Share Share
    Acrotech Announces the Publication of Data From a Phase 1 Study of BELEODAQ®
    Acrotech Announces the Publication of Data From a Phase 1 Study of BELEODAQ®

    26 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210426005126/en

    BUSINESSWIRE
    26 Apr 2021
    Share Share
    Deals and M&As this week: Alnylam Pharmaceuticals, Novartis
    Deals and M&As this week: Alnylam Pharmaceuticals, Novartis

    25 Jan 2019

    // PHARMA TECH

    https://www.pharmaceutical-technology.com/news/deals-and-mas-this-week-alnylam-pharmaceuticals-novartis/

    PHARMA TECH
    25 Jan 2019
    Share Share
    Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M
    Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M

    18 Jan 2019

    // Alaric Dearment MEDCITY NEWS

    https://medcitynews.com/2019/01/spectrum-pharmaceuticals-sells-marketed-drugs-to-aurobindo-subsidiary-for-up-to-300m/?rf=1

    Alaric Dearment MEDCITY NEWS
    18 Jan 2019
    Share Share
    Beleodaq (belinostat) : Spectrum Pharmaceuticals vs. Fresenius Kabi
    Beleodaq (belinostat) : Spectrum Pharmaceuticals vs. Fresenius Kabi

    19 Oct 2018

    // PATENT LITIGATION

    https://insight.rpxcorp.com/litigation_documents/13091411

    PATENT LITIGATION
    19 Oct 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Beleodaq 206256 (Belinostat) Injection
    FDA Confirms Paragraph IV Patent Challenge of Beleodaq 206256 (Belinostat) Injection

    01 Sep 2018

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-beleodaq-206256-belinostat-injection-1535779818.pdf

    FDA
    01 Sep 2018
    Share Share